Navigation Links
Gen-Probe Files for US Regulatory Clearance of PANTHER™ System, Fully Automated and Integrated Molecular Testing Instrument
Date:5/20/2011

SAN DIEGO, May 20, 2011 /PRNewswire/ -- Gen-Probe Incorporated (NASDAQ: GPRO) announced today that the Company has filed a 510(k) application with the US Food and Drug Administration for its PANTHER™ system, a fully automated and integrated molecular testing system designed with the flexibility to handle a wide range of testing needs.

"Filing our US regulatory application for the PANTHER system on-time is another important milestone in our efforts to create differentiated value for our laboratory customers," said Carl Hull, Gen-Probe's president and chief executive officer.  "We believe the PANTHER system will revolutionize molecular diagnostics by offering customers high levels of productivity and instrument flexibility that were once reserved for high-throughput clinical chemistry and immunoassay systems."

Gen-Probe filed for regulatory clearance to run the APTIMA Combo 2® assay, the Company's market-leading dual test for the common sexually transmitted infections Chlamydia and gonorrhea, on the PANTHER system.  Several other qualitative and quantitative assays are being developed for the system.  Over time, these new assays will enable customers to increase efficiency by consolidating testing on the PANTHER platform.

Key features of the PANTHER system include:

  • Fully integrated "sample-in, result-out" automation.  A single operator can process 275 samples in eight hours on the PANTHER system, yielding 550 Chlamydia and gonorrhea results with the APTIMA Combo 2 assay.  Hands-on time is less than an hour, resulting in more than seven hours of walk-away freedom.  For larger customers, the PANTHER system can continue running unattended, processing 500 samples (1,000 Chlamydia and gonorrhea results) in 12 hours.  These automation features can help laboratory customers manage chronic labor shortages.
  • Primary tube sampling with random access loading for maximum flexibility and productivity.  Multiple assays can be run from a single sample, and operators have continuous access to samples, reagents and consumables.
  • A customer-driven design, intuitive software for ease of use, and remote diagnostics capabilities.
  • Extensive process controls that include positive sample identification, liquid level detection, reagent dispense verification, and radio frequency identification (RFID) tags on fluid containers.  These controls help reduce the potential for manual errors.
  • A small footprint with a width of 48", a depth of 32", and a height of 69".

The PANTHER system complements Gen-Probe's TIGRIS® system, which was the first fully automated, high-throughput molecular testing system for large laboratories.  Since its launch in 2004, more than 550 TIGRIS systems have been installed at high-volume clinical diagnostic and blood screening laboratories around the world.  TIGRIS can process as many as 1,000 patient samples in a day, yielding 2,000 Chlamydia and gonorrhea results with the APTIMA Combo 2 assay.

The PANTHER system was CE-marked for sale in the European Union late in 2010.

About Gen-Probe

Gen-Probe is a global leader in the development, manufacture and marketing of rapid, accurate and cost-effective molecular diagnostic products and services that are used primarily to diagnose human diseases, screen donated human blood, and ensure transplant compatibility.  Gen-Probe is headquartered in San Diego and employs approximately 1,400 people. For more information, go to www.gen-probe.com.

Caution Regarding Forward-Looking Statements

Any statements in this news release about our expectations, beliefs, plans, objectives, assumptions or future events or performance are forward-looking statements.  These statements are often made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would.  For example, statements concerning possible or expected results of operations, regulatory approvals, future sales, growth opportunities, and plans of management are all forward-looking statements.  Forward-looking statements are not guarantees of performance.  They involve known and unknown risks, uncertainties and assumptions that may cause actual results to differ materially from those expressed or implied.  Some of these risks include: (i) the risk that the PANTHER system will not be cleared for marketing in the United States; (ii) the risk that other assays will not be approved for use on the PANTHER system; (iii) the possibility that the market for the sale of our PANTHER system or other new products  may not develop as expected; (iv) the risk that our intellectual property surrounding the PANTHER system will be invalidated; and (v) the risk that we may not be able to compete effectively.  This list includes some, but not all, of the factors that could affect our ability to achieve results described in any forward-looking statements.  For additional information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we file with the SEC.  We assume no obligation and expressly disclaim any duty to update forward-looking statements to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.

Contact:
Michael Watts
Vice president, investor relations and
corporate communications
858-410-8673


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Gen-Probe Announces Webcast of Third Quarter 2007 Earnings Conference Call
2. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
3. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
4. Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
5. Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk
6. Gen-Probe to Webcast Two Upcoming Investor Presentations
7. Neogen Acquires Gen-Probes BioKits Food Safety Business
8. Patrick J. Sullivan Elected to Gen-Probe Board of Directors
9. Gen-Probe Files US Regulatory Application for Molecular Test to Detect Common Sexually Transmitted Disease Trichomonas Vaginalis
10. Gen-Probe Announces Webcast of Third Quarter 2010 Earnings Conference Call
11. Gen-Probe to Webcast Two Upcoming Investor Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the addition of the ... ... energy-based aesthetic devices market to grow at a CAGR of 8.12% ... Aesthetic Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:3/29/2017)... , March 29, 2017  BioSpecifics Technologies ... and continues to develop collagenase based-therapies with a ... (CCH) marketed as XIAFLEX ®  in the U.S. ... will present a corporate overview at the upcoming ... Wednesday, April 5, 2017 at 8:00 a.m. ET ...
(Date:3/29/2017)... , Mar. 29, 2017 Research ... Navigation Systems Market 2014 - 2025" report to their ... ... reach USD 303.7 million by 2025. Increasing geriatric population prone ... demand for orthopedic navigation systems over the forecast period. Osteoarthritis ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... ARI Network Services, Inc. (NASDAQ: ARIS) ... eligible dealer websites for its network of more than 650 U.S.-based dealers. Rhino, a ... equipment including rotary and flail mowers and cutters, rear blades, post hole diggers, pasture ...
(Date:3/29/2017)... FL (PRWEB) , ... March 30, 2017 , ... Grass pollen is the main cause ... allergic to the stuff. The season for grass pollen runs from May to July each ... a hay fever victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an ...
(Date:3/29/2017)... ... ... Brand EXOUS Bodygear announced today a special sale price for the EX-701 Knee ... the price will be only $19.97. The EXOUS Bodygear 65cm exercise ball ... $19.97). , The special promotional prices are to help individuals get their products at ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based on research from ... employers face in trying to balance both short-term and long-term benefits demands. ... to the growing complexity, companies are finding that the short-term strategies used to ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... and other outpatient facilities, and who are the most active developers? , ... Revista and Healthcare Real Estate Insights (HREI) found that outpatient medical real estate ...
Breaking Medicine News(10 mins):